About Bioatla (BCAB)
BioAtla, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
- USD0.38
- USD0.39
- USD0.36
- USD2.53
- -22.00%
- 11M
- 1.13M
- 515.91k
- 22M
- 0.24
- -69.90%
Stock News
2 hours ago
Jobs report shows 147,000 new hires in June. Bigger-than-expected gain to keep Fed from cutting interest rates soon.
MarketWatch
3 hours ago
An Intrinsic Calculation For Exelon Corporation (NASDAQ:EXC) Suggests It's 43% Undervalued
Yahoo
6 hours ago
The Digital Economy - Critical Minerals And Equity Markets
SeekingAlpha
6 hours ago
I'm Buying Income Machines With 7-11% Yields
SeekingAlpha
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
